VBI Vaccines (VBIV) Competitors

Hookipa Pharma (NASDAQ:HOOK) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Does the MarketBeat Community prefer HOOK or VBIV?

VBI Vaccines received 412 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 73.64% of users gave VBI Vaccines an outperform vote while only 69.84% of users gave Hookipa Pharma an outperform vote.

Company	Underperform	Outperform
Hookipa Pharma	Outperform Votes 88 69.84%	Underperform Votes 38 30.16%
VBI Vaccines	Outperform Votes 500 73.64%	Underperform Votes 179 26.36%

Does the media refer more to HOOK or VBIV?

In the previous week, Hookipa Pharma had 7 more articles in the media than VBI Vaccines. MarketBeat recorded 11 mentions for Hookipa Pharma and 4 mentions for VBI Vaccines. Hookipa Pharma's average media sentiment score of 0.72 beat VBI Vaccines' score of 0.46 indicating that VBI Vaccines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hookipa Pharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VBI Vaccines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in HOOK or VBIV?

63.9% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are owned by institutional investors. 3.3% of Hookipa Pharma shares are owned by company insiders. Comparatively, 10.4% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has preferable valuation and earnings, HOOK or VBIV?

Hookipa Pharma has higher revenue and earnings than VBI Vaccines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hookipa Pharma	$20.13M	3.02	-$81.58M	-$5.00	-1.23
VBI Vaccines	$8.68M	1.85	-$92.84M	N/A	N/A

Do analysts recommend HOOK or VBIV?

Hookipa Pharma presently has a consensus target price of $43.25, indicating a potential upside of 603.25%. Given VBI Vaccines' higher probable upside, research analysts clearly believe Hookipa Pharma is more favorable than VBI Vaccines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
VBI Vaccines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is HOOK or VBIV more profitable?

Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -881.79%. VBI Vaccines' return on equity of -33.33% beat Hookipa Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hookipa Pharma	-88.73%	-33.33%	-20.22%
VBI Vaccines	-881.79%	-525.42%	-45.87%

Which has more risk & volatility, HOOK or VBIV?

Hookipa Pharma has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Summary

Hookipa Pharma beats VBI Vaccines on 10 of the 15 factors compared between the two stocks.